Pampers vs Sanofi

10-K Financial Filing Analysis for Pampers (2026-08-04)

The Procter & Gamble Company reported its annual results for the fiscal year ended June 30, 2026, delivering net sales of $87.03 billion, up 3% year-over-year, supported by organic sales growth of 1%. Operating income decreased 3% to $19.75 billion due to a 100 bps reduction in gross margin (to 50.2%) driven by unfavorable product mix, increased commodity costs, and restructuring charges, alongside higher marketing expenditures. Net earnings attributable to P&G remained stable at $16.05 billion, with diluted EPS rising 2% to $6.62, aided by share repurchases and lower net non-operating costs. Cash generation remained robust, with operating cash flow reaching $19.56 billion and adjusted free cash flow productivity achieving 100%. Strategically, P&G continued executing its multi-year productivity and organizational restructuring program while expanding its portfolio, notably announcing the acquisition of Thorne for $3.8 billion.

• Net sales reached $87,032,000,000 in FY 2026, representing a 3% reported increase (1% organic growth), while operating income decreased 3% to $19,748,000,000.
• Net earnings attributable to Procter & Gamble were $16,046,000,000 ($6.62 diluted EPS, up 2%), with Core EPS reaching $6.89.
• Generated $19,556,000,000 in operating cash flow and $15,835,000,000 in adjusted free cash flow, while agreeing to acquire Thorne for $3.8 billion.

Sanofi and Regeneron expand global Alliance with multiple next-generation, long-acting immunology antibodies

Press Release: Sanofi and Regeneron expand global Alliance with multiple next-generation, long-acting immunology antibodies

6-K Financial Filing Analysis for Sanofi (2026-08-06)

Sanofi filed a Form 6-K on August 6, 2026, incorporating a press release announcing European Union approval for MenQuadfi. The vaccine has received expanded marketing authorization in the EU for immunization against invasive meningococcal disease in infants starting from six weeks of age. This regulatory milestone expands the target patient demographic for MenQuadfi, bolstering Sanofi Vaccines' pediatric portfolio and competitive standing across European healthcare markets.

• MenQuadfi received EU regulatory approval for protection against invasive meningococcal disease in infants from age six weeks.
• The official press release detailing the approval was issued on August 4, 2026, and submitted via Form 6-K on August 6, 2026.

6-K Financial Filing Analysis for Sanofi (2026-09-17)

On September 17, 2026, Sanofi submitted a Form 6-K filing with the U.S. Securities and Exchange Commission incorporating a press release dated September 14, 2026. The filing announces a new strategic partnership between Sanofi and Cheplapharm focused on mature medicines. This partnership reflects Sanofi's ongoing portfolio optimization strategy, allowing the company to streamline operations, monetize or efficiently manage established pharmaceutical assets, and reallocate focus and capital toward core growth drivers and innovative pipeline therapies.

• Sanofi entered into a strategic partnership with Cheplapharm focused on its mature medicines portfolio, originally announced via press release on September 14, 2026.
• The Form 6-K regulatory submission was formally executed and signed on September 17, 2026, by Alexandra Roger, Head of Legal Corporate & Finance.